Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAI NASDAQ:BCAX NASDAQ:CABA NASDAQ:HCM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Beckley$7.22+1.0%$4.59$2.81▼$7.22$2.63B1.5618.43 million shs41.81 million shsBCAXBicara Therapeutics$27.76+0.6%$23.94$9.57▼$30.99$1.81B-0.81945,114 shs471,676 shsCABACabaletta Bio$2.83+6.0%$3.22$1.26▼$4.23$435.36M3.265.74 million shs3.51 million shsHCMHUTCHMED$10.84-6.6%$11.24$9.77▼$19.50$2.03B0.2447,207 shs49,332 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Beckley+0.98%+39.65%+77.40%+79.16%+167.41%BCAXBicara Therapeutics+0.58%-3.98%+21.12%+15.62%+157.28%CABACabaletta Bio+5.99%-4.71%-0.35%-17.73%+67.46%HCMHUTCHMED-6.63%-2.08%+7.11%-31.13%-36.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Beckley$7.22+1.0%$4.59$2.81▼$7.22$2.63B1.5618.43 million shs41.81 million shsBCAXBicara Therapeutics$27.76+0.6%$23.94$9.57▼$30.99$1.81B-0.81945,114 shs471,676 shsCABACabaletta Bio$2.83+6.0%$3.22$1.26▼$4.23$435.36M3.265.74 million shs3.51 million shsHCMHUTCHMED$10.84-6.6%$11.24$9.77▼$19.50$2.03B0.2447,207 shs49,332 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Beckley+0.98%+39.65%+77.40%+79.16%+167.41%BCAXBicara Therapeutics+0.58%-3.98%+21.12%+15.62%+157.28%CABACabaletta Bio+5.99%-4.71%-0.35%-17.73%+67.46%HCMHUTCHMED-6.63%-2.08%+7.11%-31.13%-36.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIAtai Beckley 2.53Moderate Buy$14.0694.77% UpsideBCAXBicara Therapeutics 2.73Moderate Buy$30.279.05% UpsideCABACabaletta Bio 2.57Moderate Buy$15.50447.70% UpsideHCMHUTCHMED 2.20Hold$15.3041.14% UpsideCurrent Analyst Ratings BreakdownLatest CABA, HCM, ATAI, and BCAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026ATAIAtai Beckley TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold7/17/2026ATAIAtai Beckley JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold7/16/2026ATAIAtai Beckley Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$10.00 ➝ $7.507/16/2026ATAIAtai Beckley GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/16/2026ATAIAtai Beckley Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral7/16/2026ATAIAtai Beckley Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold7/16/2026ATAIAtai Beckley Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold7/16/2026ATAIAtai Beckley Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.007/13/2026ATAIAtai Beckley Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/7/2026ATAIAtai Beckley Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $17.007/7/2026HCMHUTCHMED Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $17.00(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIAtai Beckley$4.09M649.92N/AN/A$0.69 per share10.46BCAXBicara TherapeuticsN/AN/AN/AN/A$7.33 per shareN/ACABACabaletta BioN/AN/AN/AN/A$1.16 per shareN/AHCMHUTCHMED$548.51M3.45$2.52 per share4.31$7.17 per share1.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIAtai Beckley-$660.05M-$2.23N/AN/AN/A-19,019.44%-89.79%-63.58%8/13/2026 (Estimated)BCAXBicara Therapeutics-$137.95M-$2.78N/AN/AN/AN/A-35.89%-33.78%8/11/2026 (Estimated)CABACabaletta Bio-$167.86M-$1.96N/AN/AN/AN/A-131.58%-96.46%8/6/2026 (Estimated)HCMHUTCHMED$456.91MN/AN/A38.71N/AN/AN/AN/A7/30/2026 (Estimated)Latest CABA, HCM, ATAI, and BCAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026ATAIAtai Beckley-$0.10N/AN/AN/A$0.11 millionN/A8/11/2026Q2 2026BCAXBicara Therapeutics-$0.80N/AN/AN/AN/AN/A8/6/2026Q2 2026CABACabaletta Bio-$0.37N/AN/AN/A$1.67 millionN/A7/30/2026H1 2026HCMHUTCHMED$0.15N/AN/AN/A$306.40 millionN/A5/14/2026Q1 2026CABACabaletta Bio-$0.41-$0.39+$0.02-$0.39$1.67 millionN/A5/12/2026Q4 2025ATAIAtai Beckley-$0.11-$0.08+$0.03-$0.08$0.22 million$0.95 million5/11/2026Q1 2026BCAXBicara Therapeutics-$0.72-$0.93-$0.21-$0.93N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATAIAtai BeckleyN/AN/AN/AN/AN/ABCAXBicara TherapeuticsN/AN/AN/AN/AN/ACABACabaletta BioN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIAtai BeckleyN/AN/AN/ABCAXBicara TherapeuticsN/A13.8513.85CABACabaletta BioN/A2.952.95HCMHUTCHMED0.054.964.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIAtai Beckley28.41%BCAXBicara TherapeuticsN/ACABACabaletta BioN/AHCMHUTCHMED8.82%Insider OwnershipCompanyInsider OwnershipATAIAtai Beckley19.80%BCAXBicara Therapeutics13.80%CABACabaletta Bio6.44%HCMHUTCHMED3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIAtai Beckley80368.17 million295.27 millionOptionableBCAXBicara Therapeutics3265.70 million56.64 millionN/ACABACabaletta Bio50163.05 million152.55 millionOptionableHCMHUTCHMED1,796174.47 million168.19 millionNot OptionableCABA, HCM, ATAI, and BCAX HeadlinesRecent News About These CompaniesHUTCHMED (NASDAQ:HCM) Stock Price Down 6% - Here's WhyJuly 17 at 12:19 PM | marketbeat.comHUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET AmplificationJuly 2, 2026 | globenewswire.comHUTCHMED to Announce 2026 Half-Year Financial ResultsJune 30, 2026 | globenewswire.comHUTCHMED's experimental drug shows durable responses in advanced bile duct cancer trialJune 25, 2026 | msn.comSyndio Acquires Embrace.aiJune 23, 2026 | businesswire.comisolved Introduces Autonomous AI Agents Built to Own HR Outcomes — Brings Unified HCM Platform to Anthropic's Claude Connectors DirectoryJune 16, 2026 | globenewswire.comEdgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)June 16, 2026 | prnewswire.comisolved Honors Top-Performing Partners at Annual Connect for Partners EventJune 15, 2026 | globenewswire.comisolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and EmployeesJune 15, 2026 | globenewswire.comPaychex Recognized as a Top WorkTech Company by TIMEJune 15, 2026 | globenewswire.comHUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 CongressJune 11, 2026 | globenewswire.comHUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual MeetingMay 21, 2026 | globenewswire.comInnovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally ...May 21, 2026 | uk.finance.yahoo.comHUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally ...May 21, 2026 | markets.businessinsider.comHUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell CarcinomaMay 21, 2026 | globenewswire.comAward-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) SuitesMay 20, 2026 | globenewswire.comAward-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) PlatformsMay 18, 2026 | globenewswire.comChengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutationsMay 13, 2026 | globenewswire.comHutchmed progresses China NDA for sovleplenibApril 29, 2026 | thepharmaletter.comTHUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaApril 29, 2026 | markets.businessinsider.comHutchmed China (NASDAQ:HCM) Gains Attention Amid Healthcare MomentumApril 21, 2026 | kalkinemedia.comKNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCABA, HCM, ATAI, and BCAX Company DescriptionsAtai Beckley NASDAQ:ATAI$7.22 +0.07 (+0.98%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$7.15 -0.07 (-0.97%) As of 07/17/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Bicara Therapeutics NASDAQ:BCAX$27.76 +0.16 (+0.58%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$27.93 +0.17 (+0.61%) As of 07/17/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Cabaletta Bio NASDAQ:CABA$2.83 +0.16 (+5.99%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$2.82 0.00 (-0.18%) As of 07/17/2026 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.HUTCHMED NASDAQ:HCM$10.84 -0.77 (-6.63%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$10.91 +0.07 (+0.65%) As of 07/17/2026 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector GE Aerospace Faces a Prove-It Moment in Q2 Earnings Sandisk: What the Chart Is Trying to Tell Us Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Has Broadcom Become Too Expensive for Its AI Story? 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
